{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053978","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.139372+00:00","generated_at":"2026-06-02T18:31:17.252997+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corbus Q1 net loss narrows to $6.9M; raised $116M, cash runway through Q1 2027","bullets":["Net loss of $6.9M ($0.83/diluted share) vs $17.7M ($4.24) in Q1 2023, driven by lower operating expenses.","Raised $116M in Q1 via public offering ($94.5M) and ATM ($21.1M); cash, equivalents & investments $120.1M.","Phase 1 data for CRB-701 (next-gen Nectin-4 ADC) to be presented at ASCO 2024 on June 1, 2024.","Appointed Dr. Dominic Smethurst as Chief Medical Officer; expects first CRB-913 patient dosed in Q1 2025.","IND cleared for CRB-601 (anti-αvβ8 mAb); Phase 1 initiation expected summer 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053978","json":"https://secwatch.observer/filing/0000950170-24-053978.json","markdown":"https://secwatch.observer/filing/0000950170-24-053978.md","text":"https://secwatch.observer/filing/0000950170-24-053978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/0000950170-24-053978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/crbp-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:31:17.252997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d9e09189da66943fa961fef876e1822b196ae90","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the three months ended March 31, 2024 results: net income approximately $6.9 million, EPS a net loss per diluted share of $0.83.","evidence_excerpt":"The Company reported a net loss of approximately $6.9 million, or a net loss per diluted share of $0.83, for the three months ended March 31, 2024, compared to a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/0000950170-24-053978-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"approximately $6.9 million"},{"label":"EPS","value":"a net loss per diluted share of $0.83"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}